TCL Archive Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone April 10, 1987
TCL Archive New Immunotherapy Increased Survival Of Neuroblastoma In Phase III Trial September 24, 2010